Blocking the PD-1/PD-L1 pathway with pharmacological inhibitors can enhance T-cell activity and cytotoxicity, which can significantly inhibit the tumor growth of HCC [92], but the therapeutic effect is still not optimistic. The gene discussed is CD274; the disease is hepatocellular carcinoma.